Ardelyx (NASDAQ:ARDX – Free Report) had its price objective trimmed by BTIG Research from $14.00 to $11.00 in a research note published on Monday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other brokerages also recently issued reports on ARDX. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Ardelyx in a research report on Tuesday, August 18th. TD Cowen began coverage on Ardelyx in a research note on Wednesday, November 4th. They issued a “strong-buy” rating on the stock. Zacks Research raised Ardelyx from a “strong sell” rating to a “hold” rating in a research report on Friday, October 16th. Citigroup decreased their target price on Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, Piper Sandler lowered their target price on Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ardelyx has a consensus rating of “Moderate Buy” and a consensus price target of $13.60.
Ardelyx Trading Up 4.0%
Insider Buying and Selling at Ardelyx
In related news, insider James Brady sold 15,136 shares of Ardelyx stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $58,424.96. Following the sale, the insider directly owned 245,930 shares of the company’s stock, valued at $949,289.80. This trade represents a 5.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Foster sold 8,562 shares of Ardelyx stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $33,049.32. Following the sale, the insider directly owned 409,410 shares in the company, valued at approximately $1,580,322.60. This trade represents a 2.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 126,059 shares of company stock valued at $486,588 in the last three months. Company insiders own 5.30% of the company’s stock.
Hedge Funds Weigh In On Ardelyx
Several large investors have recently added to or reduced their stakes in ARDX. BlackRock Inc. acquired a new stake in shares of Ardelyx during the 2nd quarter worth approximately $119,874,000. Jupiter Topco LLC acquired a new position in shares of Ardelyx in the second quarter valued at $27,043,000. AIGH Capital Management LLC acquired a new position in shares of Ardelyx in the second quarter valued at $16,320,000. Bank of America Corp DE raised its stake in shares of Ardelyx by 5.8% in the first quarter. Bank of America Corp DE now owns 2,336,994 shares of the biopharmaceutical company’s stock valued at $13,999,000 after purchasing an additional 128,301 shares in the last quarter. Finally, Eversept Partners LP raised its stake in shares of Ardelyx by 30.0% in the first quarter. Eversept Partners LP now owns 2,229,446 shares of the biopharmaceutical company’s stock valued at $13,354,000 after purchasing an additional 514,317 shares in the last quarter. Institutional investors and hedge funds own 58.92% of the company’s stock.
Key Stories Impacting Ardelyx
These are some of the ARDX stories that stood out recently:
- Neutral Sentiment: Ardelyx plans to participate in a fireside chat at the Jefferies Global Healthcare Conference on November 17. The event could provide an opportunity for updates, but no new business information was announced. Ardelyx conference announcement
- Negative Sentiment: Several law firms are publicizing the November 16 lead-plaintiff deadline for an existing securities class action covering investors who bought shares between January 2025 and August 2026. The complaint alleges Ardelyx executives made sales projections for XPHOZAH and IBSRELA while payer-access barriers were developing. These are allegations, not established findings, but the litigation creates uncertainty and potential reputational and financial risks. Class-action notice and allegations
- Negative Sentiment: Traders bought about 20,015 ARDX put options, roughly 466% above the typical volume. The spike may reflect increased demand for downside protection or bearish positioning, though options activity alone does not establish the market’s outlook.
About Ardelyx
Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.
Further Reading
- Five stocks we like better than Ardelyx
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
